AUTHOR=Pemmaraju Naveen , Sasaki Koji , Johnson Daniel , Daver Naval , Afshar-Kharghan Vahid , Chen Merry , Ahmed Sairah , Colen Rivka R. , Kwon Michael , Huh Yang , Borthakur Gautam 

TITLE=Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature

JOURNAL=Frontiers in Oncology

VOLUME=Volume 5 - 2015

YEAR=2015

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2015.00029

DOI=10.3389/fonc.2015.00029

ISSN=2234-943X

ABSTRACT=<p>Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML) patients with an incidence rate of 6.3% (<xref ref-type="bibr" rid="B1">1</xref>). Bleeding disorders related to disseminated intravascular coagulation (DIC) are common complications in AML cases (<xref ref-type="bibr" rid="B2">2</xref>). Recombinant activated Factor VII [rFVIIa (NovoSeven<sup>®</sup>)] is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in patients with congenital FVII deficiency. Use of rFVIIa for the treatment of acute hemorrhage in patients without hemophilia has been successful (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Herein, we describe the successful use of rFVIIa in a patient with acute ICH in the setting of newly diagnosed AML.</p>